Vestal Point Capital LP Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

Vestal Point Capital LP purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 400,000 shares of the company's stock, valued at approximately $5,080,000. Vestal Point Capital LP owned 1.71% of UroGen Pharma as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after buying an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after acquiring an additional 5,890 shares during the period. ProShare Advisors LLC acquired a new position in UroGen Pharma in the 2nd quarter valued at $199,000. Intech Investment Management LLC bought a new stake in shares of UroGen Pharma during the 3rd quarter valued at $155,000. Finally, SG Americas Securities LLC acquired a new stake in shares of UroGen Pharma during the 3rd quarter worth $179,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Guggenheim began coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price target for the company. Oppenheimer reaffirmed an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, UroGen Pharma presently has an average rating of "Buy" and an average target price of $48.38.

UroGen Pharma Price Performance

Shares of NASDAQ URGN traded up $0.04 during mid-day trading on Friday, hitting $12.70. 271,534 shares of the stock traded hands, compared to its average volume of 498,239. The company has a market cap of $297.82 million, a PE ratio of -4.02 and a beta of 1.12. UroGen Pharma Ltd. has a twelve month low of $10.60 and a twelve month high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a 50 day simple moving average of $12.34 and a two-hundred day simple moving average of $13.99.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same period in the previous year, the business posted ($0.68) earnings per share. As a group, equities research analysts forecast that UroGen Pharma Ltd. will post -3.1 EPS for the current fiscal year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.